Display options
Cite
Heinemann LA, Dominh T, Assmann A, et al. VTE Risk assessment - a prognostic Model: BATER Cohort Study of young women. Thromb J. 2005;3(1):5doi: 10.1186/1477-9560-3-5.
Heinemann, L. A., Dominh, T., Assmann, A., Schramm, W., Schürmann, R., Hilpert, J., & Spannagl, M. (2005). VTE Risk assessment - a prognostic Model: BATER Cohort Study of young women. Thrombosis journal, 3(1), 5. https://doi.org/10.1186/1477-9560-3-5
Heinemann, Lothar Aj, et al. "VTE Risk assessment - a prognostic Model: BATER Cohort Study of young women." Thrombosis journal vol. 3,1 (2005): 5. doi: https://doi.org/10.1186/1477-9560-3-5
Heinemann LA, Dominh T, Assmann A, Schramm W, Schürmann R, Hilpert J, Spannagl M. VTE Risk assessment - a prognostic Model: BATER Cohort Study of young women. Thromb J. 2005 Apr 18;3(1):5. doi: 10.1186/1477-9560-3-5. PMID: 15836797; PMCID: PMC1087887.
Copy Download .nbib Format: NLM
Share it on

Thromb J. 2005 Apr 18;3(1):5. doi: 10.1186/1477-9560-3-5.

VTE Risk assessment - a prognostic Model: BATER Cohort Study of young women.

Thrombosis journal

Lothar Aj Heinemann, Thai Dominh, Anita Assmann, Wolfgang Schramm, Rolf Schürmann, Jan Hilpert, Michael Spannagl

Affiliations

  1. Centre for Epidemiology & Health Research Berlin, Invalidenstr,115, 10115 Berlin, Germany. [email protected].

PMID: 15836797 PMCID: PMC1087887 DOI: 10.1186/1477-9560-3-5

Abstract

BACKGROUND: Community-based cohort studies are not available that evaluated the predictive power of both clinical and genetic risk factors for venous thromboembolism (VTE). There is, however, clinical need to forecast the likelihood of future occurrence of VTE, at least qualitatively, to support decisions about intensity of diagnostic or preventive measures. MATERIALS AND METHODS: A 10-year observation period of the Bavarian Thromboembolic Risk (BATER) study, a cohort study of 4337 women (18-55 years), was used to develop a predictive model of VTE based on clinical and genetic variables at baseline (1993). The objective was to prepare a probabilistic scheme that discriminates women with virtually no VTE risk from those at higher levels of absolute VTE risk in the foreseeable future. A multivariate analysis determined which variables at baseline were the best predictors of a future VTE event, provided a ranking according to the predictive power, and permitted to design a simple graphic scheme to assess the individual VTE risk using five predictor variables. RESULTS: Thirty-four new confirmed VTEs occurred during the observation period of over 32,000 women-years (WYs). A model was developed mainly based on clinical information (personal history of previous VTE and family history of VTE, age, BMI) and one composite genetic risk markers (combining Factor V Leiden and Prothrombin G20210A Mutation). Four levels of increasing VTE risk were arbitrarily defined to map the prevalence in the study population: No/low risk of VTE (61.3%), moderate risk (21.1%), high risk (6.0%), very high risk of future VTE (0.9%). In 10.6% of the population the risk assessment was not possible due to lacking VTE cases. The average incidence rates for VTE in these four levels were: 4.1, 12.3, 47.2, and 170.5 per 104 WYs for no, moderate, high, and very high risk, respectively. CONCLUSION: Our prognostic tool - containing clinical information (and if available also genetic data) - seems to be worthwhile testing in medical practice in order to confirm or refute the positive findings of this study. Our cohort study will be continued to include more VTE cases and to increase predictive value of the model.

References

  1. Blood. 1994 Aug 15;84(4):1031-5 - PubMed
  2. N Engl J Med. 1995 Jun 22;332(25):1661-5 - PubMed
  3. Semin Thromb Hemost. 1998;24(5):423-30 - PubMed
  4. Thromb Haemost. 2002 May;87(5):918 - PubMed
  5. Lancet. 2003 Aug 16;362(9383):523-6 - PubMed
  6. Ann Intern Med. 2001 Sep 4;135(5):322-7 - PubMed
  7. Contraception. 2002 Mar;65(3):207-14 - PubMed
  8. Dtsch Med Wochenschr. 2000 Jan 7;125(1-2):2-6 - PubMed
  9. J Thromb Haemost. 2003 Aug;1(8):1724-9 - PubMed
  10. Ann Intern Med. 1997 Apr 1;126(7):528-31 - PubMed
  11. Blood. 2002 Mar 15;99(6):1938-42 - PubMed
  12. Ann Intern Med. 2004 Mar 2;140(5):330-7 - PubMed
  13. Blood Coagul Fibrinolysis. 1992 Oct;3(5):547-53 - PubMed
  14. Eur J Vasc Endovasc Surg. 2003 Jan;25(1):1-5 - PubMed
  15. Eur Heart J. 2003 Nov;24(21):1903-11 - PubMed
  16. N Engl J Med. 2004 Jul 15;351(3):268-77 - PubMed
  17. Clin Chem. 2001 Feb;47(2):333-5 - PubMed
  18. Eur Heart J. 2003 May;24(10):937-45 - PubMed
  19. Eur J Cardiovasc Prev Rehabil. 2003 Aug;10(4):S1-S10 - PubMed

Publication Types